<DOC>
	<DOCNO>NCT02610712</DOCNO>
	<brief_summary>The purpose study determine efficacy use intravenous low-dose ketamine treatment treatment-resistant depression ( TRD ) , well change Glutamate neurotransmission inflammatory serum marker .</brief_summary>
	<brief_title>Clinical Trial Use Ketamine Treatment Resistant Depression</brief_title>
	<detailed_description>The purpose study determine efficacy use intravenous low-dose ketamine ( 0.5 mg/kg ) treatment treatment-resistant depression ( TRD ) , well change Glutamate neurotransmission measure Magnetic Resonance Imaging Spectroscopy inflammatory serum marker ( IL-6 , TNF-alpha ) .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>TreatmentResistant Depression ( Failure respond two trial antidepressant monotherapy failure respond four trial different antidepressant therapy ) Acceptance participation via informed consent Psychiatric comorbidity ( except anxiety relate disorder ) Substance abuse dependence previous 3 month Evidence structural abnormality brain imaging Pregnancy Previous hypersensitivity ketamine Heart failure insufficiency Familial personal history psychosis Glaucoma Major neurological disease Uncontrolled systemic arterial hypertension MRI contraindication Nonacceptance participation via informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>ketamine</keyword>
	<keyword>treatment-resistant</keyword>
	<keyword>depression</keyword>
	<keyword>spectroscopy</keyword>
	<keyword>neuroinflammation</keyword>
</DOC>